Vaxcell-Bio Therapeutics Co., Ltd. (KOSDAQ:323990)
South Korea · Delayed Price · Currency is KRW 10,500
+160 (1.55%)
At close: Dec 5, 2025
Vaxcell-Bio Therapeutics Revenue
In the year 2024, Vaxcell-Bio Therapeutics had annual revenue of 1.90B KRW with 13,737.28% growth. Vaxcell-Bio Therapeutics had revenue of 921.53M in the quarter ending December 31, 2024, with 6,615.06% growth.
Revenue
1.90B
Revenue Growth
+13,737.28%
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
n/a
Market Cap
244.20B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1.90B | 1.89B | 13,737.28% |
| Dec 31, 2023 | 13.72M | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Samsung Electronics | 315.56T |
| Hyundai Motor Company | 186.04T |
| Kia Corporation | 113.20T |
| SK hynix | 84.09T |
| LG Energy Solution | 23.98T |
| Hanwha Aerospace | 23.11T |
| Doosan Enerbility | 16.79T |
| HD Hyundai Heavy Industries | 16.39T |